Alnylam authorizes $1 billion stock buyback, announces commercial chief's departure

Alnylam Pharmaceuticals disclosed two separate corporate actions in an 8-K filed November 5, 2026, covering events from earlier that week.

On November 4, 2026, the company said that Tolga Tanguler will depart from his role as the Company's Executive Vice President, Chief Commercialization Officer in December 2026.¹ Alnylam said Mr. Tanguler and the Company intend to enter into a written agreement not later than his separation date, which will contain the terms of his departure from the Company.¹

Separately, on November 2, 2026, the Board of Directors of the Company authorized a program to repurchase up to $1.0 billion of the Company's common stock (the "2026 Repurchase Program").¹ The filing states that repurchases under the 2026 Repurchase Program may be made from time to time in open market transactions, including pursuant to trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, in privately negotiated transactions, or by other means, in each case in accordance with applicable securities laws, including Rule 10b-18 under the Exchange Act.¹

Alnylam said it anticipates repurchasing approximately $500 million of its common stock authorized under the 2026 Repurchase Program by the end of 2026 and the balance during 2027, but the timing and amount of any repurchases will depend on a number of factors, including the market price of the Company's common stock, general business and market conditions, the Company's liquidity and capital requirements and other investment opportunities.¹ The company noted that the 2026 Repurchase Program does not have an expiration date, does not obligate the Company to repurchase any particular dollar amount or number of shares, and may be modified, suspended or discontinued at any time without prior notice.¹

The filing was signed by Jeffrey V. Poulton, Executive Vice President, Chief Financial Officer.